Loading…
Evotec SE is projected to rise to $3.07 by 2027, a +10% move from its current price of $2.79. EVO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.73 | $2.79 | $2.85 | +0.05% |
| Jul 13 | $2.70 | $2.79 | $2.87 | +0.09% |
| Jul 14 | $2.69 | $2.79 | $2.89 | +0.14% |
| Jul 15 | $2.67 | $2.79 | $2.91 | +0.18% |
| Jul 16 | $2.66 | $2.79 | $2.93 | +0.23% |
| Jul 17 | $2.65 | $2.79 | $2.94 | +0.28% |
| Jul 18 | $2.64 | $2.79 | $2.96 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.64 | $2.79 | $2.96 | +0.32% |
| Week 2 | $2.59 | $2.80 | $3.04 | +0.64% |
| Week 3 | $2.55 | $2.81 | $3.10 | +0.97% |
| Week 4 | $2.52 | $2.82 | $3.16 | +1.29% |
| Week 5 | $2.49 | $2.83 | $3.21 | +1.62% |
| Week 6 | $2.47 | $2.84 | $3.26 | +1.94% |
| Week 7 | $2.45 | $2.85 | $3.31 | +2.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases.
It is also developing central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB.
Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions.
The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Evotec SE (EVO) is a healthcare company focused on drug discovery and development with a global footprint and collaboration networks. The stock is currently priced at $2.74, and its market capitalization stands at $973.22M, with a market ranking of 2560.
The near-term outlook shows a neutral stance, while the longer-term forecast envisions sustained bullish momentum, with the average price rising across multiple years and substantial upside potential by 2050. These figures are presented year by year, highlighting a path from a neutral start toward significant long-run gains.
A major floor 17.5% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 10.2% above — a clean break opens room to run.
A major ceiling 19.1% above — clearing it would confirm fresh momentum.
Key EVO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EVO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.84 | Sell | $2.82 | Sell |
| MA 10 | $2.83 | Sell | $2.81 | Sell |
| MA 20 | $2.75 | Buy | $2.80 | Sell |
| MA 50 | $2.86 | Sell | $2.84 | Sell |
| MA 100 | $2.88 | Sell | $2.94 | Sell |
| MA 200 | $3.18 | Sell | $3.17 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.06 | Neutral |
| Stoch RSI (14) | 47.26 | Neutral |
| CCI (20) | 31.92 | Neutral |
| Williams %R (14) | -43.33 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 6.49 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 56.67 | Neutral |
| TRIX (15) | -0.10 | Sell |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 53.42 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 2.81 | Sell |
| ADX (14) | 10.09 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is packed with caution. The sentiment is BEARISH, while the RSI14 sits at 50 and action around key moving averages eyes SMA50 at $2.93 and SMA200 at $3.22.
Near-term support is listed at $2.56 and resistance at $3.07, framing a modest trading range. The 30-day range spans from $2.31 to $3.24, illustrating a narrowed window around the current price as traders weigh the downside and upside possibilities.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.31 | $2.79 | $3.73 | 0% | Neutral | |
| $2.49 | $3.07 | $3.97 | +10% | Neutral | |
| $2.76 | $3.47 | $4.63 | +25% | Bullish | |
| $3.24 | $4.15 | $5.66 | +49% | Bullish | |
| $3.48 | $4.53 | $6.31 | +63% | Bullish | |
| $3.57 | $4.71 | $6.67 | +69% | Bullish | |
| $3.54 | $4.73 | $6.81 | +70% | Bullish | |
| $3.74 | $5.07 | $7.39 | +82% | Bullish | |
| $3.98 | $5.45 | $8.06 | +96% | Bullish | |
| $4.44 | $6.15 | $9.21 | +121% | Bullish | |
| $5.26 | $7.64 | $12.05 | +174% | Bullish | |
| $10.86 | $17.16 | $29.20 | +516% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.31 | $2.79 | $3.26 | +0.00% |
| August 2026 | $2.39 | $2.80 | $3.36 | +0.53% |
| September 2026 | $2.46 | $2.90 | $3.52 | +3.71% |
| October 2026 | $2.46 | $2.92 | $3.56 | +0.53% |
| November 2026 | $2.46 | $2.93 | $3.59 | +0.21% |
| December 2026 | $2.53 | $3.02 | $3.73 | +3.20% |
Click any year to see its month-by-month EVO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Evotec SE's 2026 outlook centres on $2.79, within a $2.31 to $3.73 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, EVO could reach as high as $3.97, with a base case around $3.07 and support toward $2.49 — roughly +10% from $2.79. Price action looks broadly range-bound.
Expect EVO to range from $2.76 to $4.63 through 2028. The $3.47 average target implies a +25% move from current prices. That is up +13% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The EVO price prediction for 2029 points to an average of $4.15 (low $3.24, high $5.66) — a potential gain of +49% on today's $2.79. Momentum favours further upside here.
In 2030, EVO is projected to trade between $3.48 and $6.31, averaging $4.53 — a potential gain of +63% from today's $2.79. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Evotec SE's 2031 outlook centres on $4.71, within a $3.57 to $6.67 range. That is up +4% on the projected 2030 average. That marks a +69% change versus current levels. Momentum favours further upside here.
By 2032, EVO could reach as high as $6.81, with a base case around $4.73 and support toward $3.54 — roughly +70% from $2.79. Buyers look set to stay in control over this stretch.
Expect EVO to range from $3.74 to $7.39 through 2033. The $5.07 average target implies a +82% move from current prices. That is up +7% on the projected 2032 average. Momentum favours further upside here.
The EVO price prediction for 2034 points to an average of $5.45 (low $3.98, high $8.06) — a potential gain of +96% on today's $2.79. Buyers look set to stay in control over this stretch.
In 2035, EVO is projected to trade between $4.44 and $9.21, averaging $6.15 — a potential gain of +121% from today's $2.79. That is up +13% on the projected 2034 average. Momentum favours further upside here.
Evotec SE's 2040 outlook centres on $7.64, within a $5.26 to $12.05 range. That is up +24% on the projected 2035 average. That marks a +174% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, EVO could reach as high as $29.20, with a base case around $17.16 and support toward $10.86 — roughly +516% from $2.79. Momentum favours further upside here.
Investing $1,000 in EVO today (≈ 359.066427 EVO) could be worth
$6,161.33
+$5,161.33 (+516%) by 2050 · US Dollar
Based on the average projected EVO price of $17.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EVOwould be worth at today's price.
$1,000 invested in EVO on Jul 10, 2025 (≈ 239.808149 EVO) would be worth
$667.87
-$332.13 (-33.2%) today · 0.67× · US Dollar
Based on a EVO entry price of $4.17 vs. today's $2.79.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.9 | $960.34 | -4.0% |
| 1 month ago | $2.61 | $1,067.05 | +6.7% |
| 3 months ago | $2.63 | $1,058.94 | +5.9% |
| 6 months ago | $3.76 | $740.69 | -25.9% |
| 1 year ago | $4.17 | $667.87 | -33.2% |
| All time (5.0y) ago | $21.68 | $128.43 | -87.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EVO forecast.
Our base-case forecast reaches $5.60 around 2035.
Implied market cap at $5.60: $1.99B
The multi-year forecast shows a path from a flat near-term outset to meaningful upside over the longer horizon. For 2026, the min price is $2.31, the avg is $2.74, the max is $3.78 with ROI of 0% and a NEUTRAL sentiment.
In 2027, the forecast projects a min of $2.34, avg $2.92, max $3.86 and a 6.7% ROI with NEUTRAL sentiment. The 2028-2029 window turns more bullish, with 2028 at avg $3.38 and 2029 at avg $4.13, yielding 23.4% and 50.9% ROI respectively. By 2030, the avg is $4.37 with a 59.4% ROI and a BULLISH sentiment, and the trajectory continues higher through 2035 (avg $5.88, ROI 114.8%).
The forecast makes clear the long-run upside: 2040 shows avg $7.14 with a 160.7% ROI and a BULLISH sentiment, while 2050 projects avg $16.32 with a 495.8% ROI and a BULLISH sentiment. The stated max prices rise to $6.28 (2030), $11.83 (2040), and $29.48 (2050). These figures indicate substantial potential upside, but they are estimates and carry uncertainty and no guarantee.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $4.37, with a min of $3.27 and a max of $6.28; ROI 59.4%; sentiment BULLISH.
The forecast starts neutral in 2026 and 2027, turns bullish from 2028 onward, with the avg price rising to $16.32 and ROI reaching 495.8% by 2050. These figures suggest upside potential but carry uncertainty and are not financial advice.
The 2035 max is $9.19, while 2040 max is $11.83 and 2050 max is $29.48. This means reaching $10 is possible in the 2040–2050 window under the forecast, but not in the 2035 peak.
The 30-day range is $2.31 to $3.24.
By 2050 the avg price is projected to $16.32 with a max of $29.48 and a ROI of 495.8%, with a BULLISH sentiment.
Evotec SE Community Discussion
0Share your Evotec SE price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.